Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderActive, not recruitingPhase 22026-10-09NCT07047118

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis Pharmaceuticals432

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
City of Hope National MedicalDuarteUnited States5
Indiana UniversityIndianapolisUnited States160
Massachusetts General HospitalBostonUnited States1015
NYU Laura and Isaac Perlmutter Cancer CenterNew YorkUnited States3
Providence Saint Johns Health CtrSanta MonicaUnited States4
Rocky Mountain Cancer CentersDenverUnited States26
Univ of Pittsburgh Cancer InstitutePittsburghUnited States2
Urology San AntonioSan AntonioUnited States17
XCancer Omaha LLCOmahaUnited States3
Yale University School Of MedicineNew HavenUnited States22